Clinical Trial Update: Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the IDH2 inhibitor enasidenib (Idhifa) in IDH2-mutated malignant sinonasal and skull base tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma
• Large Cell Neuroendocrine Carcinoma
• Olfactory Neuroblastoma
• Sinonasal Adenocarcinoma
• Sinonasal Undifferentiated Carcinoma

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma | Phase 2 | Status: RECRUITING